Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

8 questions · 8 findings · 5 reviews · Headline outcomes only

No studies found 1 · 12.5%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 25%Moderate 3 · 37.5%High 2 · 25%

DOAC vs placebo

Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

DOAC showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).

1 finding from 1 review

DOAC vs heparin

Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

DOAC showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with heparin (high certainty).

1 finding from 1 review

DOAC vs placebo

Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

DOAC showed no clear difference in bleeding‐ clinically relevant non‐major Treatment duration 28 ‐ 42… compared with placebo (moderate certainty).

1 finding from 1 review

DOAC vs heparin

Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

DOAC showed no clear difference in bleeding ‐ clinically relevant, non‐major Treatment duration 28 ‐ 42… compared with heparin (high certainty).

1 finding from 1 review

Direct oral anticoagulant (DOAC) prophylaxis vs no prophylaxis

Major bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in major bleeding compared with no prophylaxis (moderate certainty).

1 finding from 1 review